MegaPro Biomedical was awarded the Start-up Award in the 13th National Innovation Award

The outstanding core technology of niche nanomedicine, iron oxide nanoparticles developed by “MegaPro Biomedical”, a biotechnology start-up by ITRI, as well as the future nano-micelle drug carrier received the Start-up Award in the 13th National Innovation Award. After its spin-off from ITRI in 2015, the team in MegaPro Biomedical has been actively developing iron oxide[…]


Zymergen, Sumitomo Chemical and Zymergen Announce Partnership to Develop Renewable Specialty Materials

Sumitomo Chemical and Zymergen announced today they have signed a multi-year partnership to bring new specialty materials to the market. This collaboration between the two companies will enable the development of new materials to meet consumer trends in high-tech industries. Today, electronics makers and consumers seek devices that are lighter, smaller, more battery efficient, have[…]


Finch Therapeutics’ Investigational Drug CP101 Granted Breakthrough Therapy Designation from FDA for Recurrent C. Difficile Infection

February 8, 2019 TPTF invest in Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, in Series B-1 funding. Currently, Finch is actively enrolling patients with recurrent Clostridium difficile (C. difficile) infection Phase II clinical study to assess the safety and efficacy of an investigational drug CP101. The study drug is an oral capsule that is administered in a single dose.


Apexigen announces Clinical Collaboration on a New Phase 2 Trial for APX005M in Sarcoma

Apexigen today announced a collaboration with Columbia University Irving Medical Center on a new Phase 2 study for its lead immuno-oncology (I-O) therapeutic APX005M, a monoclonal antibody targeting CD40, in combination with doxorubicin and olaratumab in patients with advanced sarcomas. The trial is being funded by Apexigen and is being conducted by researchers at Columbia[…]


Zymergen, TPTF invests in Zymergen in Series C Funding led by the SoftBank Vision Fund

TPTF invested in Zymergen, the world’s first molecular manufacturing technology company, in Series C funding of over $400 million led by returning investor SoftBank Vision Fund. The round also welcomes new investors Goldman Sachs and Hanwha Asset Management, as well as returning investors, DCVC (Data Collective), True Ventures, Two Sigma Ventures, DFJ and Innovation Endeavors.[…]


MegaPro Biomedical was invited to “The Third China BioMed Innovation and Investment Conference” hosted by PhIRDA

Dr. Jassy Wang will represent MegaPro Biomedical in The Third China BioMed Innovation and Investment Conference hosted by PhIRDA in Suzhou. In addition to interacting with the key pharmaceutical, new drug, and medical equipment companies as well as investment organizations in China, she will conduct a special roadshow between 4.40pm and 5 pm on September[…]


Apexigen and Yale Cancer Center Announce Clinical Collaboration to Evaluate APX005M, Cabiralizumab, and Opdivo (Nivolumab) in Patients whose Disease has Progressed on Anti-PD-1/PD-L1 Therapy

Apexigen and Yale Cancer Center today announced a clinical trial collaboration to evaluate Apexigen’s APX005M in combination with cabiralizumab and Opdivo in patients with advanced solid tumors. The Phase 1/2 clinical trial will evaluate the safety, tolerability, and preliminary activity of APX005M in combination with cabiralizumab and Opdivo in metastatic NSCLC, metastatic melanoma and RCC patients whose disease has[…]